Avalyn Pharma (NASDAQ:AVLN) Stock Price Down 4.4% – Time to Sell?

Posted by Geri Gentry on Sep 19th, 2026

Avalyn Pharma Inc. (NASDAQ:AVLN – Get Free Report)’s share price was down 4.4% on Thursday . The company traded as low as $33.20 and last traded at $33.20. Approximately 42,641 shares traded hands during mid-day trading, a decline of 86% from the average daily volume of 310,610 shares. The stock had previously closed at $34.71.

Analysts Set New Price Targets

Several equities research analysts have issued reports on AVLN shares. Morgan Stanley increased their target price on Avalyn Pharma from $53.00 to $57.00 and gave the stock an “overweight” rating in a research report on Thursday, August 13th. Jefferies Financial Group started coverage on Avalyn Pharma in a research report on Monday, May 25th. They issued a “buy” rating and a $52.00 price target for the company. Wall Street Zen upgraded Avalyn Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Evercore began coverage on Avalyn Pharma in a report on Tuesday, May 26th. They set an “outperform” rating and a $51.00 price objective on the stock. Finally, Zacks Research upgraded Avalyn Pharma to a “hold” rating in a research note on Wednesday, May 27th. Two analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $60.00.

View Our Latest Stock Analysis on Avalyn Pharma

Avalyn Pharma Stock Down 5.7%

The company has a debt-to-equity ratio of 0.04, a current ratio of 33.12 and a quick ratio of 33.12. The company has a market cap of $1.40 billion and a price-to-earnings ratio of -1.38. The stock’s 50-day moving average is $33.33.

Avalyn Pharma (NASDAQ:AVLN – Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.98) EPS for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.05. As a group, analysts expect that Avalyn Pharma Inc. will post -3.81 EPS for the current fiscal year.

Hedge Funds Weigh In On Avalyn Pharma

Large investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp bought a new stake in shares of Avalyn Pharma in the 2nd quarter worth approximately $1,321,000. Braidwell LP purchased a new stake in Avalyn Pharma in the second quarter worth $26,382,000. Finally, Montanova Capital LLC bought a new stake in Avalyn Pharma in the second quarter valued at $82,402,000.

About Avalyn Pharma

(Get Free Report)

Avalyn Pharma is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious and progressive pulmonary diseases. The company is working to deliver established antifibrotic medicines directly to the lungs through proprietary inhalation technologies, with the goal of improving treatment and potentially reducing systemic exposure and related side effects.

Avalyn’s lead program, AP01, is an inhaled formulation of pirfenidone being developed for patients with idiopathic pulmonary fibrosis, a chronic lung disease characterized by progressive scarring and declining respiratory function.